Abstract:Recent studies have emphasized the role of peritoneal mesothelial cell (PMC) in peritoneal immune defense mechanisms in continuous ambulatory peritoneal dialysis (CAPD). The aim of this study was to evaluate a possible relationship between peritoneal dialysis effluent (PDE), cytokine (Cy) levels, and PMC viability and their impact on peritonitis morbidity. Fifteen patients initiating CAPD for end-stage renal failure participated in the study. The following parameters were evaluated: (1) the levels of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-6 (IL-6), and interleukin-8 (IL-8) in PDE samples taken 7 days after initiating CAPD, at the end of the first, third, and sixth month of CAPD (determined by a solid phase enzyme amplified sensitivity immunoassay EASIA); (2) peritoneal mesothelial cell viability [determined by the release of lactate dehydrogenase (LDH) and by trypan blue extrusion test] by isolating and culturing peritoneal mesothelial cells at the moment of the placement of the peritoneal catheter and at the sixth month of CAPD; (3) peritonitis incidence during the 24 months after starting CAPD. At the first month of CAPD in all patients there was a slight increase in PDE IL-1 beta and TNF-alpha levels, while other Cy were almost undetectable. Time course studies showed that in 10 patients (Group I) there was a significant increase in PDE levels of IL-6, IL-8, and INF-gamma (p < 0.0005) in comparison to other Cy and a good PMC viability. In the other 5 patients (Group II) there were higher PDE levels of IL-1 beta and TNF-alpha (p < 0.0005). This was associated with a marked reduction in PMC viability determined by the release of LDH and by the trypan blue extrusion test. During the 24 months after starting CAPD, incidence of peritonitis was one episode per 24 patient-months in Group I and one episode per 9.2 patient-months in Group II. Our results show that from the beginning of CAPD there are distinct patterns of Cy in the PDE that correlate with a different PMC viability and peritonitis morbidity. Thus the analysis of the above-mentioned parameters may be useful in the early identification of the risk of peritonitis, thus allowing preventive measures.

The potential role of HMGB1 release in peritoneal dialysis-related peritonitis.

Dialysate cell-free mitochondrial DNA fragments as a marker of intraperitoneal inflammation and peritoneal solute transport rate in peritoneal dialysis.

Acetylation of HMGB1 by JNK1 Signaling Promotes LPS-Induced Peritoneal Mesothelial Cells Apoptosis

IL-1β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis

Level of HIF-1α in Peritoneal Dialysate Effluent of Peritoneal Dialysis Patients and Its Relationship with TGF-β_1、IL-6、CRP and Peritoneal Function

Proinflammatory Effect of High Glucose Concentrations on HMrSV5 Cells Via the Autocrine Effect of HMGB1

Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: A retrospective study.

Lipopolysaccharide Evaluation in Peritoneal Dialysis Patients with Peritonitis

HMGB1/TLR4 Signaling Induces an Inflammatory Response Following High-Pressure Renal Pelvic Perfusion in a Porcine Model.

HMGB1 Increases Permeability of the Endothelial Cell Monolayer via RAGE and Src Family Tyrosine Kinase Pathways

High mobility group box protein-1 correlating with microinflammation and endothelial dysfunction in patients on chronic intermittent hemodialysis

Effect of dialysis-induced peritonitis on peroxisome proliferator-activated receptor γ mRNA experession of peritoneal monocyte in peritoneal dialysis patients

High Intraperitoneal Interleukin-6 Levels Predict Peritonitis in Peritoneal Dialysis Patients: A Prospective Cohort Study.

High Mobility Group Box Protein-1 Correlates with Microinflammatory State and Nutritional Status in Continuous Ambulatory Peritoneal Dialysis Patients

Expression of HMGB1 in septic serum induces vascular endothelial hyperpermeability.

Pathophysiological Function of HMGB1 As a Late- Acting Mediator of Inflammation

Increased of serum high-mobility group box chromosomal protein 1 correlated with intestinal mucosal barrier injury in patients with severe acute pancreatitis

Peritoneal dialysis effluent, cytokine levels, and peritoneal mesothelial cell viability in CAPD: a possible relationship

Elevated Expression of HDAC6 in Clinical Peritoneal Dialysis Patients and Its Pathogenic Role on Peritoneal Angiogenesis

HMGB1 as a therapeutic target in disease

HMGB1, a potent proinflammatory cytokine in sepsis.